Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib for prevention of severe chemotherapy-induced myelosuppression in bone and soft tissue sarcoma
ChiCTR2300075388Phase 4Recruiting
- Sponsor
- Shanghai Sixth People's Hospital
- Start
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of trilaciclib in bone cancer and soft tissue sarcoma (STS) (4 arms), sponsored by Shanghai Sixth People's Hospital. Primary endpoints: Duration of recurrence of severe grade 4 neutropenia, Percentage of patients with severe neutropenia during treatment and 5 more. Started Jul 2023; status: recruiting.
02
Drugs
trilaciclib
03
Conditions
bone cancersoft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2300075388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075388.